cyrilzakka/clinical-trials huggingface dataset:
Nifedipine Treatment on Uterine Contractility in IVF

The main factors associated with pregnancy rate in In Vitro Fertilization (IVF) treatment are embryo quality and the uterine ability to accept the embryo for implantation. This ability is influenced by uterine contractions (UC), which change in pattern and direction during the menstrual cycle. An abnormal uterine contraction pattern can displace the embryo from the proper position in the uterine cavity towards the cervix or the fallopian tubes and as a result may decrease pregnancy rates and increase the risk of ectopic pregnancy. Indeed, previous studies demonstrated a negative correlation between uterine contraction rate and implantation/pregnancy rates. Suppression of uterine contractions during embryo transfer can be achieved by a large array of drugs, such as cyclo-oxygenase inhibitors, β2-adrenoreceptor agonists, calcium-channel blockers, phosphodiesterase inhibitors and oxytocin antagonists. The objective of this study is to evaluate the efficacy of Nifedipine administration in reducing uterine contractility during IVF-frozen embryo transfer (FET) treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patient undergoing frozen embryo transfer

Exclusion Criteria:

* Body mass index (BMI) \> 38 kg/m2
* Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level \> 20 mIU/ml.
* Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
* Any contraindication to being pregnant and carrying a pregnancy to term.
* Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
* Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
* Irregular heart beat or already being treated with another medication for high blood pressure.
* Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
* Administration of any investigational drugs within three months prior to study enrollment.
* Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
* Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China

To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China

Compare the efficacy and safety of different thrombolytic drugs; Analysis of patients during hospital treatment of adverse events and complications; Analysis of factors that affect the effectiveness of treatment; Evaluate the pharmacological benefits of different thrombolytic drugs

Eligibility Criteria:
Inclusion Criteria:

* 1) age\> 18 years old;
* 2) meet the diagnostic criteria of China 2014 guidelines for the diagnosis and treatment of acute ischemic stroke;
* 3) no history of first sepsis or previous cerebral infarction sequelae (mRS ≤ 1);
* 4) within 3 hours of onset;
* 5) Have measurable neurological deficits;
* 6) Patients or legal guardians can understand and sign informed consent.

Exclusion Criteria:

* Absolute exclusion criteria:
* 1) history of head trauma or stroke within the last 3 months;
* 2) suspected subarachnoid hemorrhage;
* 3) history of previous intracranial hemorrhage;
* 4) intracranial tumor, arteriovenous malformation or aneurysm ;
* 5) recent intracranial or intraspinal surgery;
* 6) arterial puncture at an incurable site within the last 7 days;
* 7) elevated blood pressure: systolic blood pressure ≥180 mm Hg, or diastolic blood pressure ≥100 mm Hg;
* 8) Internal bleeding;
* 9) acute bleeding tendency, including platelet count less than 100 × 109 / L or other conditions;
* 10) heparin treatment within 48 h (APTT is outside the upper limit of normal range);
* 11) oral anticoagulant, INR\> 1.7 Or PT\> 15S;
* 12) are currently using thrombin inhibitors or factor Xa inhibitors, various sensitive laboratory abnormalities (such as APTT, INR, platelet count, ECT; TT or appropriate factor Xa activity assays) ;
* 13) Blood glucose \<50 mg / dl (2.7 mmol / L);
* 14) CT suggestive of multiple cerebral infarction (low density range\> 1/3 of the cerebral hemispheres) ;
* 15) Other conditions considered unsuitable for inclusion in this clinical study;
* 16) 3 months or are participating in other clinical trials;
* 17) combined with severe systemic disease is expected to survive less than three months.
* Relative exclusion criteria:
* 1) severe stroke (NIHSS\> 25 points);
* 2) pregnancy;
* 3) neurological deficits after epileptic seizures;
* 4) major surgery or severe trauma within the last 14 days;
* 5) Urethral hemorrhage;
* 6) Myocardial infarction within the last 3 months;
Implant Supported Single Crowns With Different Retention Modes

This study aims to examine the inflammatory response mediated by MMP-8 (Matrix metalloproteinase-8 ) level in peri-implant sulcus fluid adjacent to screw-retained, cemented or using the Acuris-system fixed single implant crowns as well as changing of the marginal bone level within the first year after implant restoration. Furthermore periodontal parameters, patient satisfaction and possible occurring biological or technical complications will be evaluated.

After giving their written consent volunteers will be screened and eligible subjects will be randomized to three different groups. In group 1 Acuris® is used as fixation type; in group 2 screw retention, and in group 3 cementation is used. After 3 months of submerged healing the dental implants will be restored with all ceramic single implant crowns, fixed by using the randomized fixation mode. Follow-up visits till one year after implant restoration will be performed. At least 11 study visits during 16 months will be conducted.

Eligibility Criteria:
Inclusion Criteria:

* capability of giving an informed consent
* good health as defined by the subjects medical history (no contraindications as described in the exclusion criteria below)
* age 18 to 99 years
* Good periodontal status: BOP \< 20%, PI \< 30%, no PD \> 4mm
* No heavy smokers (\< 10 cigarettes/day)
* at least 1 missing tooth in the premolar and molar region (with at least a mesial neighboring tooth/implant showing adequate hard- and soft tissue situation without the need of crestal hard- or soft tissue augmentation) either in the maxilla or in the mandible requiring implant therapy for reconstruction, requiring sinus floor augmentation or not.

Exclusion Criteria

* Insufficient bone volume for implant placement requiring GBR (guided bone regeneration) procedure in crestal area.
* Heavy Smokers (\>10 cigarettes/day)
* Medication with a contraindication for implant therapy (especially antiresorptive therapy, ongoing or recently completed local radiotherapy, systematic diseases, ongoing immunosuppressive therapy, functional disorders like Bruxism).
* Skeletal immaturity.
* Any active malignancy or ongoing treatment for malignancy.
* An active infection (e.g. caries, gingivitis, periodontitis) at or in the neighboring area of the operative site.
* Pregnancy
* unable or unwilling to return for follow-up visits for a period of at least 16 months
Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse. (CALYPSO)


Eligibility Criteria:
Inclusion Criteria:

* Patients with epithelial Ovarian cancer in late relapse
Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC

This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency ablation and hypofractionated proton beam radiation.

The sample size for this study was based on a non-inferiority design. Primary objective: estimate local progression-free survival (LPFS) rate in two treatments Primary endpoint: 2-year LPFS rate Expected 2-year LPFS rate in the RFA: 85% Accural time and follow up time: 24 months and 24 months, respectively. Precision for 2-year LPFS rate estimation: Allowing a difference of 15% as the non-inferiority margin, with a power of 80% and a type I error level of 5%, evaluable 68 patients are required.

Considering 5% of follow-up loss, we need 72 patients in each arm, so a total of 144 patients will be enrolled.

Eligibility Criteria:
Inclusion Criteria:

* HCC diagnosed as (i) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level greater than 200 IU/ml and a radiologically compatible feature with HCC in one or more CT/MRI/angiograms, or (ii) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level less than 200 IU/ml, and a radiologically compatible feature with HCC in two or more CT/MRI/angiograms or (iii) histological confirmation
* HCC patients who had recurrent or residual tumor after other treatments
* without evidence of extrahepatic metastasis
* the largest diameter of tumor should be less than 3cm, and the number of tumor ≤2
* no previous treatment to target tumors by other forms of RT
* liver function of Child-Pugh class A or B7 (Child-Pugh score of ≤7)
* Age of ≥18 years
* performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score
* WBC count ≥ 2,000/mm3; hemoglobin level ≥ 7.5 g/dL; platelet count ≥ 50,000/mm3; and adequate hepatic function (total bilirubin ≤ 3.0 mg/dL; AST and ALT \< 5.0× upper limit of normal; no ascites)
* no serious comorbidities other than liver cirrhosis
* written informed consent

Exclusion Criteria:

* evidence of extrahepatic metastasis
* age \< 18 years
* liver function of Child-Pugh class B8-9 and C (Child-Pugh score of \>7) or uncontrolled cases of active chronic hepatitis B
* previous history of other forms of RT adjacent to target tumors
* poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG) score
* pregnant or breast feeding status
* previous history uncontrolled other malignancies within 2 years
Comparison of the Accuracy of Different Intraocular Lens Power Calculation Formulas in Cataract Patients With Prior Radial Keratotomy

The Web-based Barret True K formula with no history formula has been proven to be a good choice for cataract patients after RK in several studies. The American society of cataract and refractive surgeons provides several IOL formulas for cataract patients who have undergone previous corneal refractive surgery. In cases where only IOL-Master data are available, Holladay 1 (Double-K) \[Holladay 1 (D-K)\] can be used for IOL power calculation in cataract patients with a history of RK. The traditional Haigis formula has also been shown to be effective for cataract patients after RK. To compare the accuracy of four intraocular lens (IOL) power calculation formulas in cataract patients after RK. They are Barrett True-K formula, Holladay 1(D-K) formula, Haigis formula, and MM formula.

Myopia is the most common cause of distance vision impairment. The prevalence of myopia has increased dramatically in the past few decades, especially in China. Corneal refractive surgery is an effective method to correct adult myopia. Radial keratotomy (RK) is one of the corneal refractive surgeries developed in the 1980s. Thirty years ago, many myopic patients underwent RK. As patients age, more and more patients have cataracts requiring cataract extraction and intraocular lens (IOL) implantation. The selection of appropriate and accurate IOL is an important factor to improve patient satisfaction. Recent studies have compared the accuracy of the newly developed IOL formula in patients with previous RK cataract. However, as a country with myopia and myopia surgery, there is no similar study in China. In addition, most patients with cataract after RK had lost ocular data before RK surgery. For RK patients without previous ocular data, how to accurately calculate the IOL power is still a clinical challenge.

Eligibility Criteria:
Inclusion Criteria:

* Had a previous history of RK surgery
* IOL-Master is available
* There were no intraoperative and postoperative complications
* Obvious refraction was performed 1 to 6 months after cataract surgery

Exclusion Criteria:

* The investigator decided that it was not suitable for this study
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods


Eligibility Criteria:
Inclusion criteria:

1. Healthy male subjects

   Exclusion criteria:
2. Any relevant deviation from healthy conditions
Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease

There is a reciprocal relationship between the central nervous system and the immune system. Stimulation of the vagus nerve results in secretion of acetylcholine (Ach) which decreases secretion of pro-inflammatory cytokines. Acetylcholine esterase is an enzyme that neutralizes Ach and thus, involves in regulation of Ach levels, and in the cholinergic tone and inflammatory state.

MicroRNAs (miRs) are evolutionarily conserved, RNAs that regulate gene expression. The investigators hypothesized that miRs controlling systemic communication processes function in one tissue in response to signals (i.e. neuronal, hormonal or others) from another.

Specifically, the investigators hypothesized that miRs control the inflammatory response in inflammatory bowel diseases through regulation of expression of messenger RNA of AchE.


Eligibility Criteria:
Inclusion Criteria:

* Inflammatory bowel disease patients under going colonoscopy

Exclusion Criteria:

* Debilitated patients who need an apotropsy
* Age \< 18 or age \> 75
* Pregnant women
* Evidence of previous or current cancer
* Inflammatory disease other than IBD
Subsymptom Threshold Exercise Protocol Following Mild TBI

The study will monitor outcomes of two interventions to develop a best practice in the treatment of mild Traumatic Brain Injury (mTBI).

The proposed pilot randomized controlled clinical trial (RCCT) will provide preliminary data to examine the effect of a novel intervention to promote brain health after mild Traumatic Brain Injury (mTBI). The study will implement a randomized controlled clinical trial of a 6 week exercise intervention (STEP) for participants with persistent mTBI symptoms, comparing STEP to standard of care practice in the controls. We will demonstrate the feasibility and acceptability of the STEP intervention. We hypothesize that STEP will lead to meaningful improvement on objective measures of self-reported mTBI symptoms, formal neuropsychological performance, and postural stability.

Eligibility Criteria:
Inclusion Criteria:

1. Participants who have sustained a concussion and have not experienced symptom resolution by 4 weeks, as indicated by a Post-Concussive Scale - Revised (PCS-R) score of 20 or higher at 4 weeks post-injury or beyond;
2. Participants are high school and college age (14-22 years old);
3. English speaking. -

Exclusion Criteria:

1. Outside of age range for the study (High school or college age)
2. Have physical injuries or comorbidities that restrict the athlete from engaging in the exercise intervention
3. Not fluent in English -
Zambia Integrated Management of Malaria and Pneumonia Study

The purpose of the study is to demonstrate the effectiveness and feasibility of community-based management of pneumonia and malaria by community health workers (CHWs) in a rural district of Zambia.

Pneumonia and malaria are the two leading causes of morbidity and mortality among children under five in sub-Saharan Africa. Due to limited access to health services in many developing countries, a number of global health organizations, including the World Health Organization, have strongly advocated the use of community health workers (CHWs) to deliver basic health care in the community and to facilitate referral to primary health facilities.

Existing supported CHWs in the study area will be trained in the assessment and classification of children between six months and five years of age presenting with fever and/or cough/difficult breathing. In the intervention arm, CHWs will be supplied with rapid diagnostic tests (RDTs), Coartem (a fixed dose combination of artemether-lumefantrine) and amoxicillin. The intervention CHWs will be trained to use RDTs in patients with reported fever and provide those with a positive result with Coartem; and patients suspected of pneumonia (based on fast breathing) will be treated with amoxicillin as per the standard of care at health facilities and monitored. In the control arm, no RDT will be performed. The CHWs will be supplied with Coartem to treat malaria/febrile illness as per the integrated management of childhood illnesses (IMCI) guidelines and patients suspected of pneumonia will be referred to the health facility for treatment as per the current practice. Data collectors will routinely visit CHWs to collect data on their consultations and follow-up patients treated by CHWs in their homes..

Eligibility Criteria:
Inclusion Criteria:

* Age between 6 months and 5 years
* Present with history of fever or reported fever
* Present with cough or difficult breathing

Exclusion Criteria:

* Age below 6 months and above 5 years
* Presence of signs and symptoms of severe illness
Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes

Patients patients enrolled in this study have a Lymphoma caused by EBV (after bone marrow transplantation, organ transplantation or patient immunodeficient.

They will receive one to three injections of allogenic CTL specific EBV.

The purpose of this study is to ensure that these injections can not cause a GVH and to study what the side effects are and to see whether this therapy might help patients with Lymphoma.

Immunological monitoring will also be studied.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, without immunosuppressed organ transplant or immunocompromised and who received a kidney transplant, or kidney-pancreas, or heart or lung or heart-lung, or liver, or cells hematopoietic stem cells, and has given its consent
* Aged 18 to 75 years Children aged more than 12 months,
* PS \<4
* Viral load determined EBV
* Life expectancy\> 1 month
* Patient typed for HLA DP DQ DR ABC
* Patients with lymphoma in the immunosuppressed associated with EBV and failure, partial response (\<50%) or relapsed after treatment with monoclonal antibodies and / or chemotherapy completed for at least three weeks. Patients with partial response may have a PET scan to confirm the lack of response.
* Patient with a measurable mass to assess the response or bone marrow infiltration and / or measurable blood and having frozen tumor material or having a repeat biopsy.
* Availability of a CTL matching at least two HLA or one HLA after validation experts with tumor cells
* test de cytotoxicity negative

Exclusion Criteria:

* Patient Pregnant or lactating
* Concurrent infection with HIV
* EBV negative lymphomas
* If acute GVHD\> grade II J-1 before injection (case grafts CSH)
* Treatment of molecules in pre-marketing authorization older than 21 days
* No matching at least two CTL HLA or non expert validation for the use of CTL with HLA sharing a single tumor
* Test of cytotoxicity positive
* Lack of recognition of tumor cells when available
The North Kynouria Project

The North Kynouria Project was initiated to study cardiovascular/stroke risk factors by employing mass screening and long-term surveillance of an adult population in the municipality of North Kynouria, in the county of Arcadia, Peloponnese, Greece. The North Kynouria Study was initiated to assess modifiable and non-modifiable determinants of cerebrovascular and coronary heart disease.

BACKGROUND:

The North Kynouria Project is a longitudinal, interventional-behavioural, prospective study aiming to identify cardiovascular/stroke risk factors, in the adult population of the municipality of North Kynouria, in the county of Arcadia, Peloponnese, Greece. The project, initiated in November 2022, recruits volunteers, of both sexes, over 18 years of age, irrespective of their personal history of cardiovascular disease. The epidemiology and burden of cardiovascular disease in North Kynouria remain unknown. The study aims to explore and document the prevalence of major cardiovascular/stroke risk factors, as well as the nutritional status, cigarette smoking, exercise habits, alcohol consumption, and overall quality of life of the inhabitants.

DESIGN NARRATIVE:

The screening exam is conducted at the Astros, Health Center, by obtaining the patient's personal history, and information about the patient's habits, such as physical activity, smoking, and alcohol consumption. Body weight, height, and waist-to-hip ratio are also measured. During the examination, blood pressure is evaluated using a pre-specified protocol, including assessment of orthostatic hypertension. Further testing includes electrocardiography, ankle-brachial index, direct ophthalmoscopy, and carotid and cardiac ultrasound. Blood samples are collected and stored at the deep freeze of the Astros premises, and blood count, lipid panel, and liver and kidney function are measured.

The main field of interest is the prevalence and burden of risk factors and cardiovascular disease in the wider region of North Kynouria, Arcadia Greece. The project aims to assess the epidemiology of CVD and consequently improve public health and engage with the local community through healthy behavioral education.

Eligibility Criteria:
Inclusion Criteria:

* residents of North Kynouria

Exclusion Criteria:

* under 18,
* pregnancy